The Kexing vaccine project contracted by the group was delivered for trial production in advance


The Kexing vaccine project contracted by the group was delivered for trial production in advance

On April 11, the Beijing Kexing vaccine project undertaken by Jinhui Group Co., Ltd. was successfully delivered to the owner for trial production nine days ahead of the original plan with the continuous efforts of more than 600 Qi'an employees.

Beijing Kexing Zhongwei project is a major national new crown vaccine production project. The total construction period is only 40 days. After the letter of acceptance was issued, Xu Bing personally took the lead and went to Beijing to set up an excellent team. He mobilized and organized more than 600 workers to plan meticulously and work overtime day and night to overcome many difficulties. He even completed the commissioning and installation of all the equipment in the core part nine days ahead of schedule, created a miracle of construction, successfully delivered it to the owner, and was highly praised by the owner, which fully demonstrated the mission of Kai'an, For the protection of human health, to fight the epidemic has made contributions!

In an interview with the news group of Jinhui group, Xu Bing, the person in charge of Jinhui, was full of emotion and told the story of the arduous journey of fighting for the science and technology development Zhongwei project for 30 days. The biggest difficulty of the project lies in the extremely short construction period, short preparation time, short supply period, more systems, small construction space, more cross operation with civil engineering, more hoisting equipment, more workers, and great management difficulty. However, Jinhui branch, with the strong support of the group company, has the courage to overcome all kinds of unimaginable difficulties, created a myth, and has made remarkable deeds( Jinhui branch / Beijing Branch)

Recommended news


The Group dispatched representatives to attend the Exchange Meeting on Construction Project Quality and Safety Management and the On-site Observation Session.

In late September, the China Construction Enterprise Management Association organized an experience-sharing and on-site observation conference on quality and safety management in construction projects in Guangzhou, which was attended by representatives from the Group.


Empowering Communities Through Health: Experts Bring Science-Based Education to Qian’an

On September 18, Jiangsu Qian’an Construction Group, in collaboration with the Science Education Base of Qidong People’s Hospital, hosted the 2026 National Science Popularization Event.


Benchmarking against global standards! The Jotun Zhangjiagang project has successfully passed the safety audit conducted by its Norwegian headquarters.

In mid-September, a foreign‑owned expert audit team from Jotun’s Norwegian headquarters conducted a three‑day, headquarter‑level specialized safety audit on the Jotun Zhangjiagang project site undertaken by the Group.


The Roche (Shanghai) project of the Group has successfully achieved 2 million safe man-hours.

On September 17, the Roche (Shanghai) Biopharmaceutical Production Base project, undertaken by the Group, successfully reached the milestone of 2 million safe man-hours.


The Group dispatched personnel to attend the training on building trustworthy quality teams in chemical engineering construction.

On September 16–17, the China Chemical Construction Enterprises Association held a training course on building “Quality‑Trusted Work Teams” in Chengdu, with representatives from the Group in attendance. The session featured a live lecture by Shi Jie, a senior expert of the Association.


Good News Abounds | The Group Has Secured Multiple Emerging Industry Projects in Succession

In the golden autumn season, bountiful harvests abound, and new‑generation growth sectors showcase their strength. Since August, leveraging its deep-rooted expertise and core competencies in industrial installation, the Group has successively won bids for five key projects in emerging productivity fields, with a total contract value exceeding RMB 250 million, injecting robust momentum into its resilient year‑end performance.